벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - fluorouracil 50 mg/ml - solution for injection/infusion - 50 mg/ml - fluorouracil 50 mg/ml - fluorouracil

벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - fluorouracil 50 mg/ml - solution for injection/infusion - 50 mg/ml - fluorouracil 50 mg/ml - fluorouracil

벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - fluorouracil 50 mg/ml - solution for injection/infusion - 50 mg/ml - fluorouracil 50 mg/ml - fluorouracil

벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - fluorouracil 50 mg/ml - solution for injection/infusion - 50 mg/ml - fluorouracil 50 mg/ml - fluorouracil

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluorouracil 50 mg/ml;  ;   - solution for injection - 50 mg/ml - active: fluorouracil 50 mg/ml     - dbl® fluorouracil injection b.p. is indicated alone or in combination for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

generics (uk) limited - fluorouracil - solution for inj/inf - 50 mg/ml - pyrimidine analogues - pyrimidine analogues - it is indicated in the treatment of the following malignancies and disease settings: in the treatment of metastatic colorectal cancer; as adjuvant treatment in colon and rectal cancer; in the treatment of advanced gastric cancer; in the treatment of advanced pancreatic cancer; in the treatment of advanced oesophageal cancer; in the treatment of advanced or metastatic breast cancer; as adjuvant treatment in patients with operable primary invasive breast cancer; in the treatment of inoperable locally advanced squamous cell carcinoma of the head and neck in previously untreated patients; in the treatment of locally recurrent or metastatic squamous cell carcinoma of the head and neck

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fluorouracil 50 mg/ml;   - solution for injection - 250 mg/5ml - active: fluorouracil 50 mg/ml   excipient: hydrochloric acid sodium hydroxide water for injection - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - fluorouracil 50 mg/ml - solution for injection - 50 mg/ml - active: fluorouracil 50 mg/ml

몰타 - 영어 - Medicines Authority

accord healthcare limited - fluorouracil - solution for infusion or injection - fluorouracil 50 mg/ml - antineoplastic agents

이스라엘 - 영어 - Ministry of Health

abic marketing ltd, israel - fluorouracil - solution for injection - fluorouracil 50 mg/ml - fluorouracil - fluorouracil - palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas, in selected patients considered incurable by surgery or other means.as leucovorin-fluorouracil chemotherapy combination for cancer treatment.